Table 4.

Multivariate analyses for evaluating the LONT effect on cancer-specific survival based on different clinicopathological factors¹

Variable	Training cohort (n = 10,612)			Validation cohort (n = 4548)
	HR	95% CI	P	HR	95% CI	P
All	0.455	0.427–0.496	< 0.001	0.446	0.401–0.496	< 0.001
N stage
N0	0.372	0.313–0.442	< 0.001	0.447	0.342–0.584	< 0.001
N1	0.389	0.330–0.459	< 0.001	0.459	0.361–0.583	< 0.001
N2	0.409	0.351–0.476	< 0.001	0.464	0.370–0.581	< 0.001
N3a	0.482	0.420–0.554	< 0.001	0.435	0.351–0.538	< 0.001
N3b	0.552	0.454–0.669	< 0.001	0.347	0.251–0.482	< 0.001
T stage
T1	0.385	0.287–0.517	< 0.001	0.431	0.272–0.682	< 0.001
T2	0.426	0.332–0.564	< 0.001	0.395	0.267–0.586	< 0.001
T3	0.432	0.386–0.484	< 0.001	0.468	0.395–0.555	< 0.001
T4a	0.493	0.432–0.563	< 0.001	0.442	0.362–0.540	< 0.001
T4b	0.328	0.260–0.415	< 0.084	0.488	0.330–0.722	< 0.001
TNM stage
I	0.413	0.323–0.528	< 0.001	0.461	0.319–0.666	< 0.001
II	0.409	0.352–0.475	< 0.001	0.443	0.354–0.555	< 0.001
III	0.442	0.405–0.482	< 0.001	0.453	0.398–0.515	< 0.001
Sex
Male	0.467	0.427–0.511	< 0.001	0.434	0.380–0.495	< 0.001
Female	0.377	0.336–0.424	< 0.001	0.458	0.381–0.551	< 0.001
Age years
≤ 60	0.398	0.349–0.454	< 0.001	0.406	0.330–0.499	< 0.001
> 60	0.446	0.409–0.485	< 0.001	0.425	0.399–0.512	< 0.001
Differentiation
G1	0.462	0.282–0.756	0.002	0.327	0.167–0.641	0.001
G2	0.385	0.329–0.451	< 0.001	0.521	0.418–0.650	< 0.001
G3 + G4	0.443	0.408–0.480	< 0.001	0.432	0.381–0.489	< 0.001
Location
Cardiac	0.528	0.460–0.605	< 0.001	0.478	0.390–0.585	< 0.001
Non-Cardiac	0.391	0.355–0.430	< 0.001	0.422	0.366–0.486	< 0.001
Race
White	0.439	0.402–0479	< 0.001	0.451	0.396–0.515	< 0.001
Black	0.408	0.337–0.493	< 0.001	0.495	0.373–0.658	< 0.001
Others	0.440	0.375–0.516	< 0.001	0.387	0.302–0.497	< 0.001
Histology
Adenocarcinoma	0.424	0.389–0.463	< 0.001	0.445	0.392–0.506	< 0.001
MAC and SRCC	0.453	0.399–0.514	< 0.001	0.459	0.376–0.560	< 0.001
ELNs
10	0.398	0.332–0.477	< 0.001	0.518	0.395–0.681	< 0.001
11–20	0.333	0.281–0.395	< 0.001	0.265	0.202–0.348	< 0.001
> 20	0.322	0.277–0.375	< 0.001	0.303	0.237–0.387	< 0.001

CI Confidence interval, HR Hazard ratio, LONT Log odds of negative lymph nodes/T stage, MAC mucinous adenocarcinoma, SRCC signet-ring cell carcinoma

¹LONT was treated as continuous data, and adjusted by age, race, sex, location, histology type, differention and TNM stage